期刊文献+

2011年PubMed收录头痛相关文献统计分析与展望 被引量:4

A statistical analysis and perspective of headache-related papers covered in 2011 PubMed
原文传递
导出
摘要 目的研究2011年PubMed收录头痛相关文献的分布和热点,为该领域进一步深入研究提供参考。方法检索PubMed数据库2011年收录的头痛相关文献,应用文献计量学方法对论文发表的期刊、国家和主题进行统计分析。结果2011年以头痛为研究主题的文献共1527篇,美国、意大利、德国发文量位居前三,研究热点主要集中于治疗(29.60%)、病理生理学(18.66%)、病因学(16.31%)等几个方面,其中偏头痛为研究重点(54.09%),Cephalalgia为重点期刊,其发表的阴性结果的文章占论著总数的14.86%。结论当前头痛疾患的研究主要集中在偏头痛方面,研究热点主要集中于治疗、病理生理学、病因学等方面;较高比例的阴性结果文章发表值得广大作者重视。 Objective To investigate the distribution and hot spots of literatures on headache by bibliometric analysis in order to provide reference for further study. Methods Literatures that contained headache or migraine in text words published in 2011 in PubMed databases (www. ncbi. nlm. nih. gov/ Pubmed) were searched. Journals, countries and subjects were bibliometrically analysed. Results There were 3683 papers involved to headache published in PubMed in 2011, of which 1527 papers were on headache research. The number of papers on headache research published by USA was the most followed by Italy and Germany ( USA 23.25% , Italy 10.74%, Germany 5.83% ). The mainly studied subjects were therapy( 29. 60% ), pathophysiology ( 18.66% ) and etiology ( 16. 31% ). 14. 86% papers published in Cephalalgia, which is one of the most important journals, reported negative results. Conclusion The emphasis of headache research was on migraine. Therapy, pathophysiology and etiology were the hot spot. Literatures with nezative result attracted authors to give the more attention.
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第1期34-37,共4页 Chinese Journal of Internal Medicine
基金 国家自然科学基金(81171058、30970417)
关键词 头痛 偏头痛 PUBMED 文献计量学 Headache Migraine PubMed Bibliometry
  • 相关文献

参考文献19

  • 1Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache, 2012,52:582-591.
  • 2Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia ,2007,27 : 193-210.
  • 3Steiner TJ, World Headache Alliance. Lifting the burden: The global campaign against headache. Lancet Neurol, 2004,3 : 204- 205.
  • 4贾向春,沈志超,邓晓群.Medline/PubMed对生物医学期刊的选刊标准和收录程序[J].中华医学图书情报杂志,2007,16(3):53-56. 被引量:32
  • 5Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia, 2004,24 Suppl 1:9-160.
  • 6Dodick DW, Kost J, Assaid C, et al. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia, 2011.31:296-300.
  • 7Lipton RB, Silberstein S, Dodiek D,et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia, 2011,31 : 18-30.
  • 8Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology ,2011,77 : 1465-1472.
  • 9Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine : pooled analyses of the 56-week PREEMPT clinical program. Headache, 2011,51 : 1358-1373.
  • 10Varkey E, Cider A, Carlsson J, et al. Exercise as migraine prophylaxis : a randomized study using relaxation and topiramate as controls. Cephalalgia ,2011,31 : 1428-1438.

二级参考文献23

共引文献31

同被引文献28

  • 1胡美玲,阎国富,何威.系统性硬皮病的血管病变发病机制研究进展[J].中国麻风皮肤病杂志,2005,21(7):545-548. 被引量:8
  • 2Salvarani C, Brown RD Jr.,Calamia KT, et al. Rapidly progressive primary central nervous system vasculitis[J].Rheumatology (Oxford), 2011;50(2):349-358.
  • 3Dirnagl U, Klehmet J, Braun JS, et al. Stroke induced immunodepression:experimental evidence and clinical relevance[J].Stroke, 2007;38(2):770-773.
  • 4Hajj-hli RA, Calabrese LH. Primary angiitis of the central nervous system[J], hutoimmun Rev, 2013;12(4):463-466.
  • 5Salvarani C, grown RD Jr.,Calamia KT, et al. Efficacy of tumor necrosis factor alpha blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment[J]. Arthritis Rheum, 2008;15:59(2):291-296.
  • 6Natoli J L, Manaek A, Dean B, et al. Global prevalence of chronic migraine : a systematic review [ J ]. Cephalalgi- a, 2010,30(5) :599-609.
  • 7Steiner T J, Stovner L J, Birbeck G L. Migraine: the seventh disabler [ J] Cephalalgia, 2013,33 ( 5 ) : 289- 290.
  • 8Headache Classification Committee of the International Headache Society ( IHS). The International Classification of Headache Disorders, 3rd edition ( beta version) [ J ]. Cephalagia, 2013,33 ( 9 ) : 629-808.
  • 9Huskisson E C, Janes J, Scott P J. Application of visual- Analogue scales to the measurement of functional capacity [J]. Rheumatol Rehabil, 1976,15(3) :185-187.
  • 10Chankrachang S, Arayawiehanont A, Poungvarin N, et al. Prophylactic botulinum type A toxin complex (Dys- port?) for migraine without aura[ J]. Headache, 2011,51 (1) :52-63.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部